EGFR and non-small cell lung carcinoma: A patient with G796S exhibited sensitivity to gefitinib after progression on osimertinib treatment, while dacomitinib showed little efficacy in five EGFR-mutated NSCLC patients with compound mutations, owing to the decreased binding affinity of dacomitinib to EGFR mediated by L792H and L718Q [101, 102].